ArticleFrontiers in medicine2022
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Drug-related pulmonary fibrosis: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System.Medicine · 2026Article
- Long-term radiologic trajectories and corticosteroid strategies in COVID-19 patients with pre-existing ILD: a 24-month cohort study.BMC pulmonary medicine · 2026Article
- Progressive fibrotic interstitial lung diseases in India: national challenges and implications for global health policies.Health research policy and systems · 2025Review
- Review
- Long COVID‑19 and pregnancy: A systematic review.Biomedical reports · 2025Article
- Convergent and divergent immune aberrations in COVID-19, post-COVID-19-interstitial lung disease, and idiopathic pulmonary fibrosis.American journal of physiology. Cell physiology · 2025Article
- Impact of pneumothorax on mortality, morbidity, and hospital resource utilization in COVID-19 patients: a propensity matched analysis of nationwide inpatient sample database.BMC pulmonary medicine · 2024Article
- Cardiopulmonary Complications after Pulmonary Embolism in COVID-19.International journal of molecular sciences · 2024Article
- Efficacy of respiratory rehabilitation in patients with COVID-19: a retrospective study.BMC pulmonary medicine · 2024Article
- Lung function at three months after hospitalization due to COVID‑19 pneumonia: Comparison of alpha, delta and omicron variant predominance periods.Experimental and therapeutic medicine · 2024Article
- Three-dimensional analysis of hard and soft tissue changes in skeletal class II patients with high mandibular plane angle undergoing surgery.Scientific reports · 2024Article
- Evaluation of Global Post-Outbreak COVID-19 Treatment Interventions: A Systematic Review and Bibliometric Analysis of Randomized Controlled Trials.Journal of multidisciplinary healthcare · 2023Review
- Immune-mediated lung diseases: A narrative review.Frontiers in medicine · 2023Review
- Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study.Frontiers in public health · 2023Article
- Changes on computed tomography in post-acute COVID-19 syndrome: systematic review and meta-analysis.Radiologia brasileiraReview
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-acute sequelae of COVID-19 seem to be an emerging global crisis. Machine learning radiographic models have great potential for meticulous evaluation of post-COVID-19 interstitial lung disease (ILD). Methods: In this multicenter, retrospective study, we included consecutive patients that had been evaluated 3 months following severe acute respiratory syndrome coronavirus 2 infection between 01/02/2021 and 12/5/2022. High-resolution computed tomography was evaluated through Imbio Lung Texture Analysis 2.1. Results: Two hundred thirty-two ( Conclusion: Post-COVID-19-ILD represents an emerging entity. A substantial minority of patients presents with fibrotic lung disease and might experience benefit from antifibrotic initiation at the time point that fibrotic-like changes are "immature." Machine learning radiographic models could be of major significance for accurate radiographic evaluation and subsequently for the guidance of therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.